(Q37442649)

20 August 2017

1 reference

title

Interactive diagnostics in the indication to allogeneic SCT in AML. (English)

1 reference

20 August 2017

7

T Haferlach

1 reference

20 August 2017

2

C Haferlach

1 reference

20 August 2017

3

S Schnittger

1 reference

20 August 2017

U Bacher

1

1 reference

20 August 2017

W Kern

series ordinal

4

1 reference

20 August 2017

N Kroeger

series ordinal

5

1 reference

20 August 2017

A R Zander

series ordinal

6

1 reference

20 August 2017

language of work or name

English

0 references

publication date

13 April 2009

1 reference

Bone Marrow Transplantation

20 August 2017

published in

1 reference

20 August 2017

volume

43

1 reference

20 August 2017

issue

10

1 reference

20 August 2017

page(s)

745-756

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2009.54

20 August 2017

exact match

0 references

cites work

Diagnostic pathways in acute leukemias: a proposal for a multimodal approach

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Implications of NRAS mutations in AML: a study of 2502 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Determination of minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Favorable impact of the t(9;11) in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

How good is allogeneic transplantation for high-risk patients with AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Modifying chromatin and concepts of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Translocation t(8;16)(p11;p13) in acute non-lymphocytic leukemia: report on two new cases and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

21 January 2018

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Risk assessment in patients with acute myeloid leukemia and a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Wilms' tumour gene 1 (WT1) in human neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Gene expression profiling as a tool for the diagnosis of acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Attitudes of terminally ill cancer patients about euthanasia and assisted suicide: predominance of psychosocial determinants and beliefs over symptom distress and subsequent survival.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Prognostic impact of t(9;11) in childhood acute myeloid leukemia (AML)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Molecular characterization of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Acute myeloid leukaemia with t(8;16)(p11;p13) in a child after intrauterine X-ray exposure

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.54

7 January 2021

Identifiers

DOI

10.1038/BMT.2009.54

1 reference

20 August 2017

1 reference